Literature DB >> 11956140

Osteoblastic response to the defective matrix in the osteogenesis imperfecta murine (oim) mouse.

I Kalajzic1, J Terzic, Z Rumboldt, K Mack, A Naprta, F Ledgard, G Gronowicz, S H Clark, D W Rowe.   

Abstract

This work examines the cellular pathophysiology associated with the weakened bone matrix found in a murine model of osteogenesis imperfecta murine (oim). Histomorphometric analysis of oim/oim bone showed significantly diminished bone mass, and the osteoblast and osteoclast histomorphometric parameters were increased in the oim/oim mice, compared with wild-type (+/+) mice. To assess osteoblast activity, a rat Col1a1 promoter linked to the chloramphenicol acetyltransferase reporter transgene was bred into the oim model. At 8 d and 1 month of age, no difference in transgene activity between oim and control mice was observed. However, at 3 months of age, chloramphenicol acetyl transferase activity was elevated in oim/oim;Tg/Tg, compared with +/+;Tg/Tg and oim/+;Tg/Tg. High levels of urinary pyridinoline crosslinks in the oim/oim;Tg/Tg mice were present at all ages, reflecting continuing high bone resorption. Our data portray a state of ineffective osteogenesis in which the mutant mouse never accumulates a normal quantity of bone matrix. However, it is only after the completion of the rapid growth phase that the high activity of the oim/oim osteoblast can compensate for the high rate of bone resorption. This relationship between bone formation and resorption may explain why the severity of osteogenesis imperfecta decreases after puberty is completed. The ability to quantify high bone turnover and advantages of using a transgene that reflects osteoblast lineage activity make this a useful model for studying interventions designed to improve the bone strength in osteogenesis imperfecta.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2002        PMID: 11956140     DOI: 10.1210/endo.143.5.8807

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  20 in total

1.  Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine.

Authors:  Haitao Li; Xi Jiang; John Delaney; Tiziana Franceschetti; Ines Bilic-Curcic; Judy Kalinovsky; Joseph A Lorenzo; Danka Grcevic; David W Rowe; Ivo Kalajzic
Journal:  Am J Pathol       Date:  2010-03-26       Impact factor: 4.307

2.  Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.

Authors:  Kirsten Kusumi; Rose Ayoob; Sasigarn A Bowden; Susan Ingraham; John D Mahan
Journal:  J Bone Miner Metab       Date:  2014-10-16       Impact factor: 2.626

3.  Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.

Authors:  Youngjae Jeong; Salah A Daghlas; Yixia Xie; Molly A Hulbert; Ferris M Pfeiffer; Mark R Dallas; Catherine L Omosule; R Scott Pearsall; Sarah L Dallas; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2018-06-22       Impact factor: 6.741

4.  Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.

Authors:  G Brunetti; F Papadia; A Tummolo; R Fischetto; F Nicastro; L Piacente; A Ventura; G Mori; A Oranger; I Gigante; S Colucci; M Ciccarelli; M Grano; L Cavallo; M Delvecchio; M F Faienza
Journal:  Osteoporos Int       Date:  2016-02-08       Impact factor: 4.507

5.  Bone resorptive activity of human peripheral blood mononuclear cells after fusion with polyethylene glycol.

Authors:  Edwin Manrique; Luz M Castillo; Oswaldo Lazala; Carlos A Guerrero; Orlando Acosta
Journal:  J Bone Miner Metab       Date:  2016-03-11       Impact factor: 2.626

6.  Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine.

Authors:  Brya G Matthews; Emilie Roeder; Xi Wang; Hector Leonardo Aguila; Sun-Kyeong Lee; Danka Grcevic; Ivo Kalajzic
Journal:  Bone       Date:  2017-06-07       Impact factor: 4.398

7.  How tough is brittle bone? Investigating osteogenesis imperfecta in mouse bone.

Authors:  R O Ritchie; S J Shefelbine; A Carriero; E A Zimmermann; A Paluszny; S Y Tang; H Bale; B Busse; T Alliston; G Kazakia
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

8.  Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors.

Authors:  Thomas E Uveges; Patricia Collin-Osdoby; Wayne A Cabral; Felicia Ledgard; Leah Goldberg; Clemens Bergwitz; Antonella Forlino; Philip Osdoby; Gloria A Gronowicz; Joan C Marini
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

9.  Increased resorptive activity and accompanying morphological alterations in osteoclasts derived from the oim/oim mouse model of osteogenesis imperfecta.

Authors:  Hao Zhang; Stephen B Doty; Christine Hughes; David Dempster; Nancy Pleshko Camacho
Journal:  J Cell Biochem       Date:  2007-11-01       Impact factor: 4.429

10.  Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development.

Authors:  Mikala Egeblad; H-C Jennifer Shen; Danielle J Behonick; Lisa Wilmes; Alexandra Eichten; Lidiya V Korets; Farrah Kheradmand; Zena Werb; Lisa M Coussens
Journal:  Dev Dyn       Date:  2007-06       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.